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statistical comparison between a subjects quantitative brain
assessments of brain functions of healthy individuals, or a
database of quantitative assessments of brain functions of
individuals known to have been Suffering from chronic pain
as a result of the abnormal brain function condition. Diagno
sis and assessment may be accomplished using a neuroimag
ing device to sense and generate images representing central
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ity, and using a computing device to command the sensory
stimulation device and neuroimaging device to test for the
presence of central pain.
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mathematical correlation models of symptom severity as a function of brain activities
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METHOD AND APPARATUS FOR
DAGNOSING AND ASSESSING
CENTRALIZED PAN
TECHNICAL FIELD

0001. The present invention relates generally to the field of
diagnosing central pain disorders. More specifically, the
present invention relates to methods and apparatuses for diag
nosing abnormal pain processing function or mechanisms in
the brain that result in central pain disorders in human Sub
jects.
BACKGROUND

0002 Nociceptive pain is known to arise from stimulation
of peripheral nerve endings. In response to such stimulation,
a peripheral nerve ending generates a peripheral nociceptive
signal that is then transmitted through the spinal cord to the
brain, where it is processed through numerous pain-process
ing networks. Descending pathways from the brain to the
spinal cord Subsequently modulate pain signals, thereby
increasing or decreasing pain perception.
0003. However, it is also known that enhanced activation
of central pain-processing pathways and networks, through
mechanisms such as neuroplastic changes in central neuronal
activity and network connectivity, can lead to spontaneous
pain in the absence of peripheral nociceptive input. When this
occurs, pain is said to have “centralized, which results in
lower pain thresholds, secondary hyperalgesia in uninjured
areas, and Sustained pain potentiation. Brain-related central
pain (also known as “centralized pain') is thought to play a
prominent role in chronic pain conditions.
0004 Central pain is generally thought of as an outcome
of central sensitivity (CS), which is also known as central
sensitization, central augmentation, and central hypersensi
tivity among other terms. CS mechanisms in the brain have
been implicated in the pathology of allodynia, which is the
term used to describe a condition where pain is caused by a
stimulus that does not normally provoke pain. CS mecha
nisms in the brain have also been implicated in hyperalgesia,
which is the term used to describe a condition in which pain
perceived from a stimulus is greater than what would nor
mally be expected from that stimulus. Put simply, in central
sensitivity the brain magnifies painful stimuli and eventually
magnifies even associated non-painful stimuli. As pointed out
in Latremoliere and Woolfe (1), because CS results from
changes in the properties of neurons in the central nervous
system, the pain is no longer coupled, as acute nociceptive
pain is, to the presence, intensity, or duration of noxious
peripheral stimuliarising from neuropathic and/or inflamma
tory sources. Further, in chronic pain conditions the increased
excitability caused by CS far outlasts the initiating noxious
stimulus, that is, the nociceptive input that causes the pain to
occur in the first place.
0005 Before CS was discovered, typically only two mod
els of pain were contemplated. The first is the aforementioned
nociceptive pain model, by which specific pain pathways are
activated by peripheral pain stimuli, and the amplitude and
duration of the pain experienced is determined entirely by the
intensity and timing of the peripheral pain inputs. The second
model contemplates gate controls in the central nervous sys
tem that open and close, thus enabling or preventing pain.
Medical science now recognizes CS as a third and unique
model that contemplates neuroplastic changes in the func
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tional properties and network connectivity of the central ner
Vous system. For example, the level of resting brain activity
within multiple networks (e.g. functional network connectiv
ity and effective network connectivity) is now known to be
associated with spontaneous pain in patients having central
pain (2, 3). CS leads to reductions in pain threshold, increases
in the magnitude and duration of responses to noxious input,
and permits normally innocuous inputs to generate pain sen
sations. In addition, CS is also believed to be relevant in

Somatic symptoms associated with painful conditions,
including but not limited to fatigue and sleep disorders.
0006. The brain's role in CS is being increasingly revealed
and understood in neuroscience, due in large part to the
advent of functional brain imaging technologies. For
example, Lee et al. (4) used functional magnetic resonance
imaging (fMRI) to examine the extent to which brain activity
contributes to the maintenance of CS in humans. When the

intensity of pain during CS was matched to the intensity of
pain during normal states, activity within the brainstem,
including the mesencephalic pontine reticular formation and
the anterior thalami, remained at an increased level during
CS. Regarding brain areas related to the consequence of
increased pain perception during CS, cortical activity, mainly
in the primary Somatosensory area, has been significantly
correlated with the intensity of pain attributable to both the
force of noxious stimulation used, and the state in which

noxious stimulation was applied.
0007 Borsook et al. (5) reviewed the literature on brain
activity using neuroimaging technologies. Their review
details evidence of alterations in multiple sub-cortical and
cortical processing mechanisms. Those alterations include
sensory, emotional/affective, cognitive, and modulatory sys
tems that are present in chronic pain. The authors note these
findings provide evidence that increases understanding of the
importance of the role of numerous brain regions in the cen
tralization of pain and the contributions of those regions to the
altered brain states associated with chronic pain conditions.
Similarly, Schweinhardt and Bushnell (6) review neuroimag
ing evidence of the active and enhanced modulatory role that
the brain plays in pain processing in chronic pain patients.
Schwienhardt and Bushnell also cite findings that brain acti
Vations in chronic pain involve brain circuitry not normally
activated by acute nociceptive pain.
0008 Because of this emerging understanding, the role of
CS is increasingly being shown to be pathological in seem
ingly unrelated chronic pain conditions and syndromes
including fibromyalgia, complex regional pain syndrome,
phantom pain, and migraine headaches. Yunus (7) identifies
no less than 14 common syndromes that lack structural
pathology yet have CS as a common mechanism. These con
ditions further include chronic fatigue syndrome, irritable
bowel syndrome, tension-type headaches, temporomandibu
lar disorder, myofascial pain syndrome, regional soft-tissue
pain syndrome, restless leg syndrome, periodic limb move
ments in sleep, multiple chemical sensitivity, primary dys
menorrhea, female urethral syndrome, interstitial cystitis,
and post-traumatic stress disorder. Yunus also notes that CS
may play a significant role in the pain associated with depres
sion and in Gulf War Syndrome.
0009 Giesecke et al. (8) used fMRI to demonstrate aug
mented central pain processing in patients with idiopathic
chronic low back pain and fibromyalgia. Indeed, when equal
levels of mechanical pressure intended to elicit a painful
response were applied to patients and to normal controls,
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patients with chronic low back pain and fibromyalgia expe
rienced significantly more pain and showed more extensive,
common patterns of neuronal activation in pain-related cor
tical areas of the brain than did the controls. Thus, CS may
play an important role in persons with chronic low back pain
that persists without identifiable physical pathology.
0010. The role of CS in persistent inflammatory condi
tions is also gaining recognition. In Gwilym et al. (9), fMRI
illustrated significantly greater brainactivation in osteoarthri
tis (OA) patients in response to stimulation of their referred
pain areas (i.e. areas where pain persists but do not exhibitOA
or related inflammation) compared with healthy controls, and
the magnitude of this activation positively correlated with the
extent of neuropathic-like elements to the patient’s pain. The
role of CS in osteoarthritis has been the subject of several
other investigations (10, 11, 12). As detailed in Imamura et al.
(13), the refractory, disabling pain associated with knee OA is
usually treated with total knee replacement. However, a com
parison of OA patients with healthy normal controls showed
patients with knee OA had significantly lower pressure pain
thresholds (PPT) over widespread evaluated structures
beyond the knee. The lower PPT values were correlated with
higher pain intensity, higher disability Scores, and with poorer
quality of life. This suggests that pain in these patients might
be more associated with CS than with peripheral inflamma
tion and injury. As the authors point out, the implications of
the role of CS, and its potential for modulation, may provide
exciting and innovative cost effective therapeutic tools to
control pain, reduce disability, and improve quality of life in
knee OA patients.
0011. The diagnosis of pain generally fails to differentiate
central pain processes in the brain from peripheral pain aris
ing from an ongoing noxious stimulus. Diagnosing central
pain is usually only made empirically after multiple failed
therapeutic attempts reveal its likely presence. This practice
results in unmet expectations for both patients and physi
cians, and contributes to high healthcare costs in the chronic
pain clinical population. The ability to develop quantitative
real-time diagnostic and assessment methods for central pain,
especially methods and apparatuses making Such diagnosis
and assessment practical at the point-of-care, would be a
significant clinical advancement. Such would improve phy
sicians’ ability to appropriately and immediately match treat
ments to the relevant pain mechanism, thus saving time and
reducing healthcare costs.
0012. Of relevance to the present invention, it is known
that neurophysiologic information may be obtained by tech
niques such as electroencephalography (EEG) and fMRI. It is
also known that fMRI can be used to measure neurotransmit

ter and neuroreceptor activity. It is also known that the analy
sis of numerous brain imaging and functional measures,
including EEG measures (13), have been shown to produce
measures related to brain networks and network connectivity
that correlate to findings produced by fMRI imaging (14).
Thus, the presence of brain activity associated with CS, and
hence central pain, can be determined using EEG measures
and analysis.
0013 The following documents are incorporated by ref
erence in their entirety:
0014 “Central sensitization: a generator of pain hypersen
sitivity by central neural plasticity'. Latremoliere A. Woolf
CJ. J. Pain. 2009 September; 10(9):895-926.
00.15 “Intrinsic brain connectivity in fibromyalgia is asso
ciated with chronic pain intensity, Napadow V. LaCount
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L. Park K, As-Sanie S, Clauw DJ, Harris R. E. Arthritis

Rheum. 2010 August: 62(8):2545-55.
0016 “Disrupted functional connectivity of the pain net
work in fibromyalgia”, Cifre I, Sitges C, Fraiman D,

Muñoz MA, Balenzuela P. González-Roldán A. Martinez

Jauand M. Birbaumer N. Chialvo DR. Montoya P. Psycho
som Med. 2012 January: 74(1):55-62.
0017 “Identifying brain activity specifically related to the
maintenance and perceptual consequence of central sensi
tization in humans', Lee MC, Zambreanu L, Menon DK.

Tracey I. J Neurosci. 2008 Nov. 5; 28(45): 11642-9.
0018. A key role of the basal ganglia in pain and analge
sia—insights gained through human functional imaging.
Borsook D, Upadhyay J, Chudler E. H. Becerra L. Mol
Pain. 2010 May 13: 6:27.
0019. “Pain imaging in health and disease—how far have
we come?'. Schweinhardt P. Bushnell M. C. J. Clin Invest.

2010 Nov. 1; 120(11):3788-97.
0020 “Fibromyalgia and overlapping disorders: the uni
fying concept of central sensitivity syndromes, Yunus M
B. Semin Arthritis Rheum. 2007 June; 36(6):339-56.
0021. “Evidence of augmented central pain processing in
idiopathic chronic low back pain'. Giesecke T. Gracely R
H, Grant MA, Nachemson A, Petzke F. Williams D A,

Clauw DJ. Arthritis Rheum. 2004 February:50(2): 613–23.
0022 “Psychophysical and functional imaging evidence
Supporting the presence of central sensitization in a cohort
of osteoarthritis patients', Gwilym S. E. Keltner J. R.
Warnaby C. E. Carr AJ, Chizh B, Chessell I, Tracey I.
Arthritis Rheum. 2009 Sep. 15: 61 (9): 1226-34.
0023 "Lessons from fibromyalgia: abnormal pain sensi
tivity in knee osteoarthritis, Bradley L. A. Kersh B C,
DeBerry J.J. Deutsch G, Alarcón GA, McLain DA. Novar
tis Found Symp. 2004; 260:258-70.
0024) “Sensitization in patients with painful knee osteoar
thritis', Arendt-Nielsen L. Nie H, Laursen MB, Laursen B
S. Madeleine P. Simonsen O H, Graven-Nielsen T. Pain.

2010 June; 149(3):573-81.
0025 “Pain mechanisms in osteoarthritis: understanding
the role of central pain and current approaches to its treat
ment, Mease PJ. Hanna S. Frakes E. P. Altman R D. J

Rheumatol. 2011 August;38(3):1546-51.
0026 "Impact of nervous system hyperalgesia on pain,
disability, and quality of life in patients with knee osteoar
thritis: a controlled analysis”. Imamura M, Imamura S. T.
Kaziyama H. H. Targino RA, Hsing W T de Souza L. P.
Cutait M M, Fregni F, Camanho G. L. Arthritis Rheum.
2008 Oct. 15:59(10): 1424-31.
0027 “Functional connectivity: the principal-component
analysis of large (PET) data sets”. Friston K.J. Frith CD,
Liddle P F, Frackowiak R. S. J. Cereb Blood Flow Metab
1993; 13:5-14.

0028 “Electrophysiological signatures of resting state
networks in the human brain'. Mantini D, Perrucci MG,
Del Gratta C, Romani GL, Corbetta M. Proc Natl Acad Sci

USA. 2007 Aug. 7: 104(32): 13170-5.
(0029 U.S. patent application Ser. No. 12/865,286 filed
Jul. 29, 2010 as a 371 of PCT/US09/32639, published on
Dec. 23, 2010 as Pub. No. US2010/324441 A1, and

assigned to the assignee of the present application;
0030 U.S. Provisional Patent Application Ser. No.
61/024,641, filed Jan. 30, 2008 and assigned to the
assignee of the present application;
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0031 U.S. Provisional patent application Ser. No. 12/865,
286, filed Jul. 29, 2010 and assigned to the assignee of the
present application;
0032 U.S. Provisional Patent Application Ser. No.
61/644,049, filed May 8, 2012 and assigned to the assignee
of the present application.
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the neuroimaging device and the sensory stimulation device
and configured to command the sensory stimulation device
and neuroimaging device. The apparatus may be configured
to perform a brain response test for the presence of central
pa1n.
BRIEF DESCRIPTION OF THE DRAWINGS

SUMMARY

0033. A method is provided for diagnosing and assessing
central pain. The method may include the steps of assessing a
subjects brain function, determining the probability that a
Subject is suffering from chronic pain as a result of an abnor
mal brain function condition by obtaining a quantitative
assessment of the Subjects brain function, and
0034) making a statistical comparison between the sub
ject’s quantitative brain function assessment and either a
database of quantitative assessments of the brain functions of
normal, healthy individuals, or a database of quantitative
assessments of the brain functions of individuals known to

have been Suffering from chronic pain as a result of the
abnormal brain function condition.

0035. The method may alternatively include assessing a
subjects brain function using a brain response test (BRT)
comprising the steps of performing one or more baseline
neuroimaging tests, causing one or more brain responses by
applying one or more sensory stimulations, and performing
one or more neuroimaging tests after the step of causing one
or more brain responses. The method may also include the
steps of obtaining a quantitative assessment of the subjects
brain function and making a statistical comparison between
the Subject’s quantitative brain function assessment and one
or more databases of quantitative assessments of the brain
functions.

0036. A method is provided for predicting symptom sever
ity in individuals having central pain. The method may
include the steps of executing a brain response test on a
Subject, obtaining measures of brain activities associated with
central pain in the Subject by analyzing findings from the
brain response testing, correlating these measures of brain
activities to measures of symptom severity, creating a math
ematical correlation model that provides symptom severity as
a function of the measures of brain activities, and Subse

quently using the mathematical correlation model to predict
symptom severity in individuals having central pain when
measures of brain activities are known.

0037. A method is provided for determining the effect of a
therapeutic intervention in alleviating symptoms of central
pain. The method may include the steps of executing a brain
response test on a Subject, obtaining measures of brain activi
ties associated with central pain in the Subject by analyzing
findings from the brain response testing, correlating these
measures of brain activities to measures of the effect of a

therapeutic intervention, creating a mathematical correlation
model that provides the effect of therapeutic intervention as a
function of the measures of brain activities, and Subsequently
using the mathematical correlation model to predict the effect
of therapeutic intervention in alleviating symptoms of central
pain when measures of brain activities are known.
0.038 An apparatus for diagnosing and assessing central
pain is provided, which may comprise a neuroimaging device
that is configured to sense and generate images representing
central nervous system function, a sensory stimulation device
that is configured to stimulate brain activities associated with
central sensitivity, and a computing device that is coupled to

0039. These and other features and advantages of the
invention will become apparent to those skilled in the art in
connection with the following detailed description and draw
ings, in which:
0040 FIG. 1 is a flow chart depicting a method for diag
nosing fibromyalgia;
0041 FIG. 2 is a flow diagram of a method of diagnosing
and assessing central pain;
0042 FIG. 3 is a flow diagram of a method of predicting
symptom severity in individuals having central pain;
0043 FIG. 4 is a flow diagram of a method of determining
the effect of a therapeutic intervention in alleviating Symp
toms of central pain; and
0044 FIG. 5 is a schematic diagram showing an embodi
ment of an apparatus for diagnosing and assessing central
pain.
DETAILED DESCRIPTION

0045. In the following description of the disclosed appa
ratus and methods, the term "central pain', which is also
known as "centralized pain', is intended to mean any form of
pain, whether chronic or acute, that is enhanced in its char
acteristics; such as magnitude, duration and scope; due to
abnormalbrain activity associated with pain processing. Such
brain activity may include, but is not limited to, central sen
sitivity and network connectivity.
0046. The term “central sensitivity” is intended to mean
any central nervous system condition pathologically related
to hyperalgesia, allodynia, reductions in pain threshold,
increases in the magnitude and duration of responses to nox
ious input, results in normally innocuous inputs to generate
pain sensations, or results in non-painful symptoms associ
ated with increases in central nervous system responsiveness.
Central sensitivity is also known by alternate terms that
include but are not limited to “central sensitization”, “central

pain', 'central augmentation.” and “central hypersensitiv
ity”.
0047 Central sensitivity is not a manifestation or cause of
an individual symptom or condition. Instead, central sensi
tivity results in a worsening of the effect or magnitude of one
or more symptoms because of a central nervous system con
dition that is independent of the cause of the one or more
symptoms per se. Thus, any method of treatment of central
sensitivity is fundamentally different from treatment of a
specific symptom. For example, treatment of pain augmenta
tion by central sensitivity is inherently different than treat
ment of pain under traditional nociceptive models of pain.
0048. The terms “network connections” and “network
connectivity” are intended to mean various forms of relation
ships between brain regions involved in processing of infor
mation Such as pain. For example, “functional connectivity”
refers to a statistical correlation between the activities of

different brain regions. “Effective connectivity” denotes not
simply a statistical but a causal influence between two brain
regions.
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0049. The term “alleviate' or “alleviating is intended to
mean the act of reducing, making less severe, mitigating,
treating, or eliminating a condition and/or its symptoms for
any period of time.
0050 Except where the context requires otherwise, the
term “comprise' and variations of the term, such as “com
prising”, “comprises” and “comprised' are not intended to be
exclusive. Where, for example, a form of the word “com
prise' is used to refer to one or more additives, components,
integers or steps; its use is not intended to exclude other
additives, components, integers or steps.
0051. Where the terms “integral” or “integrated” are used
to describe a relationship between two or more elements, the
terms are intended to indicate that such elements are joined
together in a manner that does not allow separation of ele
ments from one another without diminishing or destroying a
function of one or more of the elements.

0052. The term “stimulation signal' is intended to mean
any energy signal used in the process of stimulating a tissue
Such as a brain by transmitting an energy signal generated by
a device Such as an electrical stimulator, or a magnetic stimu
lator Such as a transcranial magnetic stimulator. Other terms
used to refer to Such a signal may include but are not limited
to “cortical stimulation”, “neuromodulation' and “neuro
stimulation'.

0053. The term “neuroimaging test” is intended to mean
any medical test that provides visual indication, measures, or
other data that can be used to make an assessment about

central nervous system function, including brain function.
Types of tests that the term “neuroimaging test may be used
to refer to include, but are not limited to, magnetic resonance
imaging, computer aided tomography, positron emission
tomography, or single photon emission computed tomogra
phy, and may also include brain electrical function tests Such
as electroencephalography or magnetoencephalography.
0054) The term “brain activities” is intended to refer to any
brain activities that are known in the art to be associated with

central sensitivity. Such brain activities are intended to
include, but are not limited to, abnormal condition, abnormal

function, abnormal response, abnormal regions of activation,
abnormal network connectivity, abnormal release of neuro
chemicals, abnormal uptake of neurochemicals, abnormal
electrical activity, or abnormal metabolism.
0055. The term “brain function' is intended to mean any
action or process of a brain that is within the brain's normal
state of operation.
0056. The term “spectral segments” is intended to mean
frequency components of an electrical signal that includes
individual frequency components, and in the case of an EEG
signal, that includes groupings of frequency components
commonly known as “frequency bands'. Such bands includ
ing, but not limited to the “delta” band (nominally 1-3.5
hertz), the “theta' band (nominally 4-7.5 hertz), the “alpha
band (nominally 8-12 hertz) and the “beta’ band (nominally
12.5-25 hertz).
0057 The term “resting EEG” is intended to mean elec
troencephalogram signals that are collected with the Subjects
eyes either open or closed and during periods of no significant
physical activity, mental activity, or any otherform of engage
ment that may cause the brain to be stimulated significantly or
engaged in elevated brain function.
0058. A method is provided for diagnosing and assessing
a brain-related chronic pain disorder. The method includes
assessing a human Subject's brain function and then deter
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mining the probability that the subject is suffering from
chronic pain related to an abnormal brain function condition
by obtaining a quantitative assessment of the Subject's brain
function and making a statistical comparison between the
Subject’s quantitative brain function assessment and a data
base of quantitative assessments of the brain functions of
individuals known to have been Suffering from chronic pain
as a result of the abnormal brain function condition. The

assessment of a Subject's brain function may include obtain
ing an electroencephalogram (EEG) of the Subjects electrical
brain activity, and the determination of the probability that the
Subject is suffering from chronic pain as a result of an abnor
mal brain function condition may include determining the
probability that the subject is suffering from a chronic pain
condition Such as fibromyalgia by obtaining a quantitative
assessment of the Subject's EEG (dEEG) and making a sta
tistical comparison between the subject’s qEEG and a data
base of qBEGs of individuals known to have been suffering
from fibromyalgia.
0059 A physical assessment may first be performed of a
human Subject presenting with a complaint of symptoms
characteristic of a chronic pain condition Such as fibromyal
gia. The physical assessment may include, among other
things, a determination of chronic widespread pain, sleep
difficulty, fatigue, morning stiffness of the muscles and joints,
cognitive difficulty and other symptoms associated with the
condition. Where, for example, fibromyalgia is suspected, the
physical assessment may also include tests performed to
exclude various non-fibromyalgia conditions as the cause of
the symptoms. Such further testing may include palpation of
18 tender points in the manner prescribed by the American
College of Rheumatology (ACR), with Such palpation being
performed to determine whether the subject has an abnormal
sensitivity to pain. Where, for example, idiopathic chronic
low back pain ICLBP) is suspected, the physical assessment
may include tests performed to exclude various non-ICLBP
conditions as the cause of the symptoms. Such further testing
may include palpation of tender points other than the 18
tender points prescribed by the ACR and/or may include
physical tests other than tender point palpation.
0060. In the absence of a definitive diagnosis, an EEG test
may be performed in addition to the physical assessment.
Specifically, the subject may be made comfortable by, for
example, being seated or reclined. Preparation of the scalp in
accordance with commonly followed procedures for per
forming a clinical EEG may be done by a person of sufficient
competence. EEG electrodes may then be adapted to be worn
on the scalp, preferably in Scalp locations identified as the
“International 10-20” standard sites, using common methods
of affixing the electrodes such that they rest on or otherwise
contact tissues.

0061 While any number of electrodes may be used, a
preferred number is either 19 or 24, in accordance with the
number of electrode sites used to construct various indepen
dent databases utilized to represent the EEG of a healthy
normal population.
0062 Records of the subject's EEG from each electrode
site may then acquired under the conditions of both their eyes
being closed and their eyes being open, with each condition
producing a separate data record. In other words, an “eyes
open EEG record may be obtained, which includes EEG data
obtained from each electrode site while the subject’s eyes are
open and an “eyes closed EEG record may be obtained,
which includes EEG data obtained from each electrode site
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while the subject’s eyes are closed. Preferably, a minimum of
five minutes of EEG data may be obtained from each elec
trode site for each "eyes open EEG record and a minimum of
five minutes of EEG data may be obtained from each elec
trode site for each "eyes closed EEG record to assure that
enough EEG data is recorded to produce statistically signifi
cant samples from each electrode site, both with the subjects
eyes open and with the subject’s eyes closed. This is further

to obtaining the TPPEEG record for the first site. This process
may be repeated for each chosen tender point. Accordingly,
the resulting EEG data record includes the TPP EEG records
acquired for each chosen tender point.
0067. The “TPP” EEG records may be acquired for a
period of time that is sufficient to extract from each “TPP

described below.

from electromyographic movement. Preferably, all EEG
records (“eyes open EEG records, “eyes closed EEG
records, and “TPP” EEG records) may be individually edited
to provide from each EEG record a minimum of 60 seconds of
clean EEG. Preferably, the clean data is obtained so as to
present a high degree of statistical consistency. Such mea
sures as “Split-Half reliability, which is the ratio of variance

0063 Preferably, an additional test may be performed in
which at least one additional EEG record is made that

includes EEG data obtained at each electrode site while pain
is elicited in the Subject. In diagnosing or assessing conditions
Such as fibromyalgia, a number of tender points on the Sub
jects body may be palpated. In this test, henceforth referred
to as a “tender point palpation (TPP) test”, a number of tender
points on the Subject’s body, preferably ranging between one
and 18 when diagnosing or assessing fibromyalgia, are iden
tified and serially palpated, preferably with an algometer.
Preferably, four tender points may be chosen, and, preferably,
those four points include tender points adjacent the right and
left lateral epicondyle of the arms, and tender points adjacent
the right and left costochondral junctions of the second rib.
While the subject’s eyes are preferably closed during this test,
it should not be confused with the “eyes closed’ test described
above.

0064. The TPP test may be executed by acquiring an EEG
record (“TPP” EEG record) including EEG data obtained
from the electrode sites for a first tender point by first com
mencing the acquisition of EEG data and then, a short period
of time later, commencing palpation of the first tender point.
Preferably, the period of time between the commencement of
data acquisition and the commencement of palpation of the
first tender point may be between one and three hundred
seconds. Palpation of the first tender point may be accom
plished by pressing on the tender point with an algometer,
preferably at a rate of approximately one kilogram per centi
meter squared per second, until the Subject reports a painful
sensation. Preferably, palpation pressure may be removed as
Soon as the Subject reports a painful sensation. A record is
made of the amount of the pressure being applied at the
moment the Subject reports a painful sensation. Although the
TPPEEG record may be obtained while the subject’s eyes are
closed, it should not be confused with the “eyes closed EEG
record described above.

0065. Further according to the TPP test method, the acqui
sition of the TPP EEG record may include continued record
ing of EEG data (with the subject’s eyes closed) for a period
of time after release of palpation pressure, preferably between
1 and 300 seconds, and most preferably, for at least 60 sec
onds. A comparison may then be made between EEG data
collected before application of palpation pressure and EEG
data collected after release of palpation pressure. This com
parison may then be used to make diagnostic findings. Such
findings may include changes in brain EEG activity, when
comparing EEG after release of palpation pressure to EEG
before palpation pressure, in specific regions of the brain
characteristic of a brain-related chronic pain condition, but
not otherwise anticipated in a healthy normal individual.
0066 Following this period, a second and subsequent ten
der point may be serially palpated, preferably with an algo
meter, in the same manner as described for the first, with TPP

EEG records being recorded for each by recording the eyes
closed EEG for each site in the manner described with regard

EEG record a minimum of 60 seconds of “clean EEG data,
that is, data free of extraneous electrical noise Such as that

between the even and odd seconds of the time series of

selected clean EEG, and “Test Re-test” reliability, which is
the ratio of variance between the first half and the second half

of the selected clean EEG segments may be used. Preferably,
clean EEG data is obtained such that measures of these ratios

are a minimum of 0.95 and 0.90 respectively, which is con
sistent with levels of reliability commonly published in EEG
literature.

0068. With regard to the TPP test method, clean data
includes that EEG data acquired after palpation of a tender
point, and does not include any EEG data acquired during the
palpation of a tender point. In addition, to assess the stability
of a TPP EEG record, EEG data acquired before palpation of
a tender point may be removed, edited and statistically com
pared to like data in the “eyes closed EEG record obtained
from the eyes closed EEG test. Stability of the “closed eyes’
and TPPEEG records is indicated by a finding that there is no
statistically significant difference between the “eyes closed
EEG record and the pre-palpation portion of the. TPP EEG
record. A contrary finding indicates instability and a need to
repeat the EEG tests.
0069. Further to the method, and in the preferred embodi
ment, clean “eyes open”, “eyes closed”, and “PPT EEG
records may be then mathematically analyzed for various
time domain and frequency domain parameters of their
respective electrical signals. These analyses may include, but
are not limited to Voltage and current analyses, frequency
spectrum analyses using methods such as a Fast Fourier
Transform or wavelet analysis, an absolute power analysis, a
relative power analysis, a phase analysis, a coherence analy
sis, an amplitude asymmetry analysis, and localization of
electrical activity in the brain using inverse EEG computation
analysis.
0070 Findings from the aforementioned analyses may
then be statistically compared to the same parameters deter
mined from “eyes open”, “eyes closed”, and “PPT EEG
records taken from an age and gender matched database of
healthy normal individuals. Such statistical analyses may
include, but are not limited to deviations from a standard

normal distribution. Findings of Statistically significant
abnormal deviation, or lack thereof, may then be presented in
a graphical or numerical format for analysis by a competent
health care professional or person of similar expertise.
(0071 EEG abnormalities consistent with those observed
in a sample population of fibromyalgia patients may include,
but are not limited to one or more of the following: (1) an
overall reduction in EEG power across all spectra in either of
the eyes open or eyes closed conditions; (2) statistically sig
nificant low EEG power levels in frontal or temporal regions
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of any of the delta (1-3.5 hertz), theta (4-7.5 hertz) or alpha
(8-12 hertz) frequency segments of EEG for the eyes closed
condition; (3) statistically significant low coherence among
the frontal EEG sites for the delta or theta EEG segments in
either of the eyes closed or eyes open conditions; (4) statisti
cally significant high relative beta (12.5-25 hertz) absolute
power in the parietal region of the brain for either of the eyes
closed or eyes open conditions. The magnitude of statistical
variation considered to be statistically "significant may vary
depending on the application. For example, in research, a
difference between a sample and a population measure gen
erally has to have a p-value of 0.01 or less for the difference to
be considered statistically “significant'. However, in clinical
application statistically significant differences may be
declared with p-values at the 0.1 level or less.
0072 Further EEG abnormalities consistent with those
observed in a sample population offibromyalgia patients, and
drawn particularly to the TPP test method, may include but
are not limited to a finding of (1) a statistically significant
increase in EEG absolute power, particularly in the alpha and
beta segments, in the parietal and occipital areas of the brain
as compared to the “eyes closed EEG record (“eyes closed
EEG findings without tender point palpation) for the same
Subject; or (2) a statistically significant increase in coherence
in the alpha or beta segment of EEG.
0073. A diagnosis of fibromyalgia may be made when
physical assessment findings that Support a diagnosis of
fibromyalgia are augmented by (1) at least one abnormal
finding resulting from the TPP test, preferably a finding of a
statistically significant increase in EEG absolute power, and
particularly in the alpha and beta segments, in the parietal and
occipital areas of the brain as compared to the eyes closed
findings without tender point palpation for the same subject;
and preferably (2) at least one abnormal finding resulting
from the eyes closed EEG test, preferably statistically signifi
cant low EEG power levels in frontal or temporal regions of
any of the delta, theta or alpha frequency segments of EEG for
the eyes closed condition, and most preferably with an addi
tional finding of statistically significantlow coherence among
the frontal EEG sites for the delta or theta EEG segments.
0074 Clean EEG records from a subject may be math
ematically analyzed for various time domain and frequency
domain parameters of their electrical signals, consistent with
analysis techniques already described, and then findings from
these mathematical analyses may be statistically compared to
like parameters taken from an age and gender matched data
base of individuals known to have fibromyalgia. The statisti
cal comparisons may include, but are not limited to deviations
from a standard normal distribution of like EEG measures
associated with members of a database of individuals known

to have fibromyalgia. The results of those comparisons may
then be presented in a graphical or numerical format for
analysis by a competent health care professional or person of
similar expertise for the existence of Statistically significant
abnormal deviations, or the lack thereof. A finding in Support
of a fibromyalgia diagnosis would be supported if there is an
absence of any significant deviation between measures from
a subjects clean EEG and those from a database comprising
individuals known to have fibromyalgia.
0075 Similarly, clean EEG from a subject may be math
ematically analyzed for various time domain and frequency
domain parameters of its electrical signals, consistent with
analysis techniques already described, and then findings from
these mathematical analyses may be statistically compared to
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like parameters determined from an age and gender matched
database of individuals known to have a chronic pain condi
tion other than fibromyalgia.
0076. The statistical comparisons may include, but are not
limited to deviations from a standard normal distribution of
like EEG measures associated with members of a database of

individuals known to have the chronic pain condition. The
results of those comparisons may then be presented in a
graphical or numerical format for analysis by a competent
health care professional or person of similar expertise for the
existence of statistically significant abnormal deviations, or
the lack thereof. A finding in Support of a chronic pain con
dition diagnosis would be supported if there is an absence of
any significant deviation between measures from a subjects
clean EEG and those from a database comprising individuals
known to have the chronic pain condition.
0077. To determine the probability that a subject belongs
to a population of individuals Suffering from fibromyalgia a
statistical comparison may be made of EEG parameters of the
Subject, as determined from the aforementioned analyses, to
like EEG parameters determined from a database of individu
als known to suffer from fibromyalgia. The statistical com
parison may include, but is not limited to, determination of
Z-Statistics associated with specific EEG measures from a
standard normal distribution determined from the database of

individuals known to suffer from fibromyalgia. Probability of
inclusion in the population of individuals Suffering from
fibromyalgia would result from findings that Subject mea
Sures cannot be excluded from the database standard normal

distribution. Assuming that the data in the database of fibro
myalgia patient EEG is normally distributed, then statistics
Such as the t-statistic or the Z-Statistic can be used to deter

mine the probability that the sample EEG belongs to the
population of fibromyalgia sufferers. If the probability is
sufficiently low (e.g. p-0.01) then a conclusion could be
made that the sample does not belong to that population.
0078 Similarly, the probability that a subject belongs to
the population of individuals suffering from a chronic pain
condition other than fibromyalgia may be determined by
making statistical comparison of EEG parameters of a Sub
ject, determined from the aforementioned analyses, to like
EEG parameters determined from a database of individuals
known to suffer from that chronic pain condition. The statis
tical comparison may include, but is not limited to, determi
nation of Z-statistics associated with specific EEG measures
from a standard normal distribution determined from the

database of individuals known to suffer from the chronic pain
condition. Probability of inclusion in the population of indi
viduals Suffering from the chronic pain condition other than
fibromyalgia would result from findings that Subject mea
Sures cannot be excluded from the database standard normal
distribution.

0079. In addition, findings from aforementioned analyses
of clean EEG records from a subject may be statistically
correlated to measures of symptom severity. As previously
described, analysis findings may be mathematically analyzed
for various time domain and frequency domain parameters of
their electrical signals. A number of measures of the magni
tude of deviation from standard normal distributions of either

healthy normal EEG, known fibromyalgia patient EEG, or
from EEG of individuals known to suffer from a chronic pain
condition other than fibromyalgia can be determined. The
magnitudes are presumed to be related to the severity of the
condition, and may be statistically correlated to Such symp

US 2015/020 1879 A1

tom measures that may include, but are not limited to tender
point pain pressure thresholds as determined by an algometer,
and various other indices of pain derived from the algometry
measures (e.g. the sum of all 18 tender point pain tolerance
measures, the average of all 18 tender point pain tolerance
measures, etc.). Such analysis has utility in both predicting
symptom severity in individuals with fibromyalgia, and in
determining the effect of therapeutic intervention to corrector
manage symptoms of fibromyalgia.
0080. Also the above-described EEG testing and statisti
cal analysis methods may be repeated on a subject following
a period of therapeutic intervention on the subject. The results
of these statistical analyses may be statistically compared to
like statistical analyses of the subject accomplished before
therapeutic intervention was started. This comparison might
include, but is not be limited to, paired t-testing statistics,
correlation analysis of changes in Symptom severity, and
Subsequent comparison to a database of age and gender
matched healthy normal individuals. The comparisons could
be used as a means of assessing the effectiveness of a chosen
therapeutic intervention, or as a means of determining if an
alternate intervention may be indicated in the absence of
treatment effect from a current therapeutic intervention. The
comparisons could also be used as a means of determining if
further therapeutic intervention may be indicated in the
absence of any abnormal findings. With regard to the TPP test,
repeat testing may include applying tender point pressure
with an algometer only to the levels required to cause a
painful response recorded in the same testing performed
before therapeutic intervention.
0081 EEG data may be acquired from a subject at a first
location (e.g. a clinical location) and the EEG data may be
transferred via electronic means to another location (e.g. a
central analysis location) for the herein described analysis
and statistical comparisons. The electronic means of data
transfer may include, but is not be limited to, data transfer
across a local area network or the internet. Analyses and
statistical findings may then be transferred from the central
analysis location to the clinical location where they can be
used in various ways by a physician or similarly qualified
health care professional for the determination of best clinical
practice and therapeutic intervention.
0082 EEG data may also be acquired from a subject at a
first location (e.g. a clinical location) and the EEG data trans
ferred via electronic means to another location (e.g. a central
analysis location) for the purpose of increasing the size of
various databases of individuals known to be suffering from
fibromyalgia, individuals known to be suffering from a
chronic pain condition other than fibromyalgia, and/or
healthy normal individuals.
0083. In testing for chronic pain conditions other than
fibromyalgia, other, more general physical tests may be per
formed. Some of those tests may include a form of tender
point palpation that differs from that typically done in testing
for fibromyalgia, and that differs in a way that makes the
testing more useful in diagnosing other chronic pain condi
tions. For example, tests involving algometer palpation may
be performed at several points on the body of a suspected
ICLBP patient, but not necessarily at the same 18 tender
points described above for diagnosing and/or assessing fibro
myalgia. Testing for ICLBP may include some other form of
tender point palpation including physical action that causes
reproduction of the back pain. Just as in the method disclosed
for diagnosing and/or assessing fibromyalgia, this general
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physical test may be done following a period of EEG collec
tion, and then additional EEG data may be captured after the
test. Further, just as in the method disclosed for diagnosing
and/or assessing fibromyalgia, differences in the EEG data
may then be analyzed and/or statistically compared to deter
mine if the result belongs to a particular chronic pain condi
tion such as ICLBP. For example, the ideal test for an ICLBP
patient might include palpation of four FM tender points and
performance of a number of other physical actions that cause
reproduction of pain specific to ICLBP patients. If the EEG
analysis then shows a negative finding for the fibromyalgia
tender points but a positive finding for the back pain actions,
then a conclusion that the patient has ICLBP would be sup
ported rather than a conclusion that the patient is Suffering
from fibromyalgia.
I0084. With reference to FIGS. 2-4, a method is provided
for diagnosing or assessing central pain such as that arising
from abnormal brain function, including but not limited to,
central sensitivity and abnormal network connectivity
involved in pain processing. The method includes assessing a
human Subject’s brain function and then determining the
probability that the subject is suffering from central pain by
obtaining a quantitative assessment of the Subject’s brain
function and making a statistical comparison between the
Subject’s quantitative brain function assessment and one or
more databases of quantitative assessments of the brain func
tions, such as a database of individuals known to be suffering
from central pain, a database of individuals known to be
suffering from pain that is not central pain, or a database of
healthy normal individuals.
I0085. The assessment of a subject's brain function may
include obtaining a neuroimaging test Such as, but not limited
to, magnetic resonance imaging, computer aided tomogra
phy, positron emission tomography, or single photon emis
sion computed tomography, and may also include brain elec
trical function tests such as electroencephalography or
magnetoencephalography. The determination of the prob
ability that the Subject is Suffering from central pain may
include determining the probability that the subject is suffer
ing from central pain by obtaining a quantitative assessment
of the Subject's neuroimaging test and making a statistical
comparison between the quantitative assessment and a data
base of like quantitative assessments of healthy individuals,
individuals known to be suffering from central pain, or indi
viduals suffering from pain that is not central pain.
I0086 A physical assessment may first be performed of a
human Subject presenting with a complaint of symptoms
characteristic of central pain, Such as chronic pain with no
clear etiology. The physical assessment may include, among
other things, a determination of chronic widespread pain,
sleep difficulty, fatigue, cognitive difficulty and other symp
toms associated with abnormal brain function involved in

central pain. In the absence of a definitive diagnosis, a diag
nostic or assessment test for central pain may be performed in
accordance with the present invention.
I0087. The method may include the step of assessing the
brain function of a subject to determine the presence of cen
tral pain, whereas the step includes, but is not limited to,
making measures of a brainactivities, e.g., of a brainfunction,
brain conditions or brain anatomy, either by direct assessment
techniques known in the art Such as neuroimaging, or by
indirect assessment Such as analysis of other biological mea
Sures. The assessment step includes use of any method known
in the art to determine the presence of any brain activity
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known to be associated with central pain, including but not
limited to, central sensitivity or abnormal levels of network
connectivity. One skilled in the art of medical assessment may
administer and interpret one or more assessments designed to
detect central pain. Such assessments may include any one or
more known neuroimaging tests. Such assessments may also
be used for detecting the presence and identifying the location
of one or more abnormal brain activities through interpreta
tion.

0088. In a preferred embodiment, a means of assessing a
brain to determine the presence of central pain in a subject
includes the use of one or more neuroimaging tests utilizing
methods and apparatuses known in the art, with the neuroim
aging tests being performed before, during and after the appli
cation of any one or more forms of sensory stimulation (SS)
intended to cause a brain response. A neuroimaging test per
formed before an SS is henceforth referred to as a “baseline'

neuroimaging test. A neuroimaging test performed after an
SS is henceforth referred to as a “post-SS neuroimaging test.
The combination of neuroimaging tests and application of
one or more sensory stimulations is henceforth referred to as
a “brain response test' (BRT). The SS includes any noxious,
pain inducing or non-painful means. In a preferred embodi
ment, a BRT may include an electroencephalogram (EEG)
test performed with eyes closed or eyes open, with at least one
additional EEG record made that includes EEG data obtained

during and after the application of any one or more forms of
an SS.

I0089. One embodiment of an SS is palpation of tender
points on the subjects body, consistent with the method
described herein as a tender point test. Other means of caus
ing a painful or noxious SS for the purposes of a BRT may
include, but are not limited to, application of mechanical
pressure on any part of the body, application of otherforms of
mechanical stimulation to any part of the body (e.g. a
"pinch'), application of an electrical stimulus, application of
aheat-producing stimulus, and in vivo or in vitro introduction
of a chemical agent meant to elicit a painful or non-painful
response. Means of causing a non-painful SS for the purposes
of a BRT may include, but are not limited to, forms of typi
cally non-painful physical contact including mechanical
brushing, controlled physical movements made by the Sub
ject, and various forms of mental processing Such as cognitive
exercises.

0090. Further to the application of an SS, the method
includes any number of applications of stimulation to elicit
any number of brain responses. For example, a single SS may
be applied to produce a single brain response. Alternately, a
series of SS applications may be made over a period of time to
produce multiple brain responses so that a BRT may include
assessing changes in brain response over time. Such series of
PS applications may include one or more applications of any
combination of noxious, painful or non-painful stimuli, with
a period of rest between each application ranging from one
second to several minutes. Such assessment of changes in
brain response may include, but are not limited to, quantifi
cation of temporal Summation of pain, also known in the pain
literature as “wind up'.
0091. The BRT test may be executed by acquiring a brain
response record using any means of neuroimaging test. In a
preferred embodiment, a brain response test EEG (“BRT
EEG') record is obtained that includes EEG data obtained for
a period of time before, during, and after the application of
any number of an SS. EEG data may be obtained from EEG
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electrode sites for a period of time, preferably ranging from
one second to 15 minutes, prior to commencement of a first
SS. During application of an SS, EEG data obtained may be
denoted as EEG collected during application of the SS. Data
collected during application of an SS may have unwanted
aspects. For example, EEG data collected during the applica
tion of an SS may also contain measurements of electromyo
graphic signals arising from muscle contractions a patient
may make as a result of feeling a sensation Such as pain.
Accordingly, the data collected during the application of an
SS may or may not be removed in Subsequent analysis
according to the method. Further to the embodiment, EEG
data may be obtained from EEG electrode sites for a period of
time, preferably ranging from one to 15 minutes, after appli
cation of an SS.

0092. Further to the BRT test method, a record is made
quantifying parameters associated with the one or more SS
being used. For example, if an SS involves palpation of a
tender point, then the location and amount of mechanical
pressure being applied at or near the time the Subject reports
a painful sensation may be recorded. Other examples of quan
tification of an SS may include, but are not limited to, the
amount of pressure on any body part required to elicit pain,
parameters of other forms of mechanical stimuli, parameters
of forms of electrical stimuli, parameters of forms of heat
stimuli, parameters of an introduced chemical agent, param
eters of brush strokes and parameters of a mental exercise.
(0093. Further to the BRT test method, the recording of
EEG may continue for a period of time after completion of
each of the one more SS applications, including a final SS
application, with the period of time preferably being between
one second and 15 minutes. The process of application of an
SS and subsequent recording of EEG may be repeated until all
intended applications of an SS are completed. Accordingly,
the resulting EEG data record includes the BRT EEG records
for all applications of SS.
(0094. The BRT EEG records may be acquired for a period
of time that is sufficient to extract from each BRT EEG record

a record of “clean EEG data, that is, EEG data that have

minimal non-EEG signals such as extraneous electrical noise
arising from, for example, instrumentation anomalies or elec
tromyographic movement. Preferably, a record of clean EEG
data is sufficient to provide enough EEG data to perform any
one of a number of EEG analyses known in the art with a
sufficiently high degree of statistical confidence. More pref
erably, all EEG records according to the method may be
individually edited to provide from each EEG record a period
comprising a minimum of 60 seconds of clean EEG. With
regard to the BRT test method, clean data preferably does not
include any EEG data acquired during the application of an
SS.

(0095. Further to the BRT test method, and in the preferred
embodiment, clean EEG records may be then mathematically
analyzed for various time domain and frequency domain
parameters of their respective electrical signals. These analy
ses may include, but are not limited to Voltage analysis, cur
rent analysis, Voltage and current analysis, frequency spec
trum analysis using Fast Fourier Transform (FFT) analysis,
frequency spectrum analysis using a wavelet analysis
method, frequency spectrum analysis using absolute power
analysis method, frequency spectrum analysis using relative
power analysis method, frequency spectrum analysis using
phase analysis method, frequency spectrum analysis using
coherence analysis method, frequency spectrum analysis
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using amplitude symmetry analysis method, phase analysis,
various forms of network analysis and source localization of
electrical activity in the brain using inverse EEG computation
analysis. The purpose of Such analyses is to determine the
presence of one or more abnormal brain activities, e.g., brain
function, brain condition, brain anatomy or related brain mea
Sures that indicate central pain Such as, but not limited to,
central sensitivity and abnormal levels of network connectiv
ity.
0096. According to the BRT test method, a finding of
central pain is made by analyzing findings from the afore
mentioned BRT analyses. Such findings may include, but are
not limited to, a determination of a brain activity associated
with central sensitivity or abnormal brain network connectiv
ity associated with pain processing. In a preferred embodi
ment, BRT EEG records may be statistically compared to the
same parameters determined from EEG records taken from
age and gender matched databases of either healthy normal
individuals or individuals that are suffering from pain that is
not central pain. Such statistical analyses may include, but are
not limited to deviations from a standard normal distribution.

Findings of statistically significant abnormal deviation, or
lack thereof, may then be presented in a graphical or numeri
cal format for analysis by a competent health care profes
sional or person of similar expertise.
0097 EEG abnormalities consistent with subjects suffer
ing from central pain may include measures indicative of
central sensitivity or abnormal network connectivity includ
ing, but not limited to one or more of the following: (1)
abnormal levels of in EEG power in spectral segments of
resting EEG measures, including but not limited to, an abnor
mal level of EEG power across the entire resting EEG spectra;
(2) abnormal levels of coherence or phase shift between at
least two resting EEG sites; (3) abnormal levels of resting
EEG relative power in particular regions of the brain.
0098. Further EEG abnormalities consistent with subjects
Suffering from central pain, and drawn particularly to the
EEG BRT test method, may include but are not limited to a
finding of (1) statistically significant increases in EEG abso
lute power, particularly in the alpha and beta segments, in the
parietal, occipital, and temporal areas of the brain as com
pared to the resting EEG record for the same subject; or (2)
statistically significant increases in coherence in spectral seg
ments of the BRT EEG record as compared to the resting EEG
record for the same subject.
0099. A determination of central pain may be made when
physical assessment findings that Supporta diagnosis of cen
tral pain are augmented by assessing a brain following a BRT.
The assessment of a BRT may include a statistical compari
son between any one or more of the subjects BRT measures
and a database of like BRT measures of either healthy normal
individuals, individuals suffering from pain that is not central
pain, or individuals suffering from central pain. Alternately,
central pain may be diagnosed by Statistically determining
one or more deviations between a subjects one or more BRT
measures and like BRT measures obtained from at least one

healthy normal individual or at least one individual suffering
from pain that is not central pain; then comparing the one or
more deviations to like deviations detected in a sample popu
lation of Subjects known to be suffering from central pain.
0100. In a preferred embodiment, clean resting EEG or
BRT EEG records from a subject may be mathematically
analyzed for various time domain and frequency domain
parameters of their electrical signals, consistent with analysis
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techniques already described, and then findings from these
mathematical analyses may be statistically compared to like
parameters taken from age and gender matched databases of
either healthy normal individuals, individuals suffering from
pain that is not central pain, or individuals known to be
Suffering from central pain. The statistical comparisons may
include, but are not limited to deviations from a standard
normal distribution of like EEG measures associated with

members of databases of healthy normal individuals, indi
viduals suffering from pain that is not central pain, or indi
viduals known to be suffering from central pain. The results
of those comparisons may then be presented in a graphical or
numerical format for analysis by a competent health care
professional or person of similar expertise for the existence of
statistically significant abnormal deviations, or the lack
thereof. A central pain diagnosis would be Supported if one or
more findings of either resting EEG or BRT EEG records are
consistent with like findings from a database comprising indi
viduals known to be suffering from central pain. More pref
erably, a central pain diagnosis would be Supported if one or
more findings of either resting EEG or BRT EEG records are
consistent with statistical significance to like findings from a
database comprising individuals known to be suffering from
central pain.
0101. Further according to the BRT test method, measures
of an abnormal brain activity, e.g., brain function, brain con
dition, brain anatomy or related brain measures arising from
analyses of BRT test findings from a subject may be corre
lated to measures of symptom severity, such as but not limited
to pain severity. Such correlation may be used to create math
ematical correlation models such as a mathematical model

that provides for symptom severity as a function of measures
of brain activities, or such as the effect of a therapeutic inter
vention as a function of measures of brain activities. Such

mathematical correlation models may subsequently be used
to predict symptom severity in individuals having central
pain, or to determine the effect of atherapeutic intervention to
alleviate symptoms of central pain, when measures of brain
activities are known.

0102. Further, BRT test analyses according to the method
may also be used for determining the location of abnormal
brain activity and further for determining points for applica
tion of therapeutic methods for alleviating central pain,
including but not limited to, cortical stimulation methods.
0103) Further, BRT testing and statistical analysis meth
ods may be repeated on a subject following a period of thera
peutic intervention on the Subject for alleviating central pain,
including but not limited to, cortical stimulation methods.
The results of these repeat statistical analyses may be statis
tically compared to like statistical analyses of the Subject
accomplished by performing BRT testing before therapeutic
intervention was started. This comparison might include, but
is not be limited to, paired t-testing statistics, correlation
analysis of changes in Symptom severity, and Subsequent
comparison to databases of either healthy normal individuals,
individuals suffering from pain that is not central pain, or
individuals known to be suffering from central pain. The
comparisons could be used as a means of assessing the effec
tiveness of a chosen therapeutic intervention, or as a means of
determining if an alternate intervention may be indicated in
the absence of treatment effect from a current therapeutic
intervention. The comparisons could also be used as a means
of determining if further therapeutic intervention may be
indicated in the absence of any abnormal findings. With
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regard to the BRT test, repeat testing may include the appli
cation of one or more SS forms. The application of the one or
more SS forms may be done in accordance with types and
parameters quantified for the same form of SS that was used
or performed before therapeutic intervention.
0104 Further according to the method, BRT test method
data may be acquired at a first location (e.g. a clinical loca
tion) and the acquired BRT test method data transferred via
electronic means to another location (e.g. a central analysis
location) for the herein described analysis and statistical com
parisons to be accomplished. The electronic means of data
transfer may include, but isn't limited to means of data trans
fer across a local area network and/or the internet. Conse

quently, analysis and statistical findings may then be trans
ferred from a central analysis location to a clinical location,
where they may be used in various ways by a physician or
similarly qualified health care professional for the diagnosis
or assessment of central pain.
0105. Further according to the method, BRT test method
data may be acquired at a first location (e.g. a clinical loca
tion) and the acquired BRT test method data transferred via
electronic means to another location (e.g. a central analysis
location) for a purpose such as inclusion or increasing the size
of various databases of individuals known to be suffering
from central pain, individuals known to be suffering from
pain that is not central pain, and healthy normal individuals.
0106 The method of diagnosis and assessment described
herein may be accomplished with any number of apparatuses
that include apparatuses for providing a neuroimaging test
and apparatuses that may be required to create a sensory
stimulation. Referring to FIG. 5, a preferred embodiment of
an apparatus 5 for diagnosing and assessing central pain may
include a neuroimaging device 1 configured to sense and
generate images representing central nervous system func
tion, and operably connected to a computing device 2 such as
a computer in a way that permits data transfer between the
neuroimaging device 1 and the computing device 2. Such
connection may be accomplished via a physical cable con
nection 4 or alternately via a wireless transfer means. The
apparatus 5 for diagnosing and assessing central pain may
further include a sensory stimulation device 3 configured to
stimulate brain activities associated with central sensitivity,
and further operably connected to a computing device 2 in a
way that permits data transfer between the sensory stimula
tion device 3 and the computing device 2. Such connection
may also be accomplished via a physical cable connection 6
or alternately via a wireless transfer means. In practice, the
apparatus 5 for diagnosing and assessing central pain is con
figured to accomplish the BRT test method described herein.
In one embodiment, the computing device 2 may be pro
grammed to operate the neuroimaging device 1 for a period of
time, and to collect data, in accordance with the BRT test

method, from the neuroimaging device 1 during that time.
After such period of time, the computing device 2 is further
programmed to Suspend data collection from the neuroimag
ing device 1 and to direct use of a sensory stimulation appa
ratus 3. Such directing of use may include signaling an opera
tor to manually use a sensory stimulation apparatus 3 on a
Subject, or may also include programming that automatically
controls and operates a sensory stimulation apparatus 3 to
create a sensory stimulation on a Subject. After use of the
sensory stimulation apparatus 3, the computing device 2 may
be programmed to further operate the neuroimaging device 1
for another period of time, and to collect additional data in
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accordance with the BRT test method from the neuroimaging
device 1 during that additional period of time. Using neu
roimaging device 1 data gathered during both periods of time,
the computing device 2 may be further programmed to per
form statistical analyses and comparisons on the data in
accordance with the BRT test method, and further to transmit

data across a network, all according to the method of diagno
sis and assessment described herein.

0107 The invention is not limited in any way to the
embodiments disclosed herein. In this regard, no attempt is
made to show structural details of the disclosed apparatuses
or process details of the disclosed methods in more detail than
is necessary for a fundamental understanding of the disclosed
apparatuses and methods. The description is intended only to
make apparent to those skilled in the art how the several forms
of the invention may be embodied in practice.
1-52. (canceled)
53. A method for diagnosing and assessing central pain, the
method including the steps of
assessing a subject’s brain function using a brain response
test (BRT) comprising the steps of:
performing one or more baseline neuroimaging tests,
causing one or more brain responses by applying one or
more sensory stimulations, and
performing one or more neuroimaging tests after the
step of causing one or more brain responses;
obtaining a quantitative assessment of the Subject's brain
function; and

making a statistical comparison between the Subjects
quantitative brain function assessment and one or more
databases of quantitative assessments of the brain func
tions.

54. The method of claim 53 in which the step of making a
statistical comparison includes making a statistical compari
son between the Subject’s quantitative brain function assess
ment and the one or more databases of quantitative assess
ments of brain functions where the one or more databases

include a database of individuals known to be suffering from
central pain, a database of individuals known to be suffering
from pain that is not central pain, or a database of healthy
normal individuals.

55. The method of claim 53 in which the step of applying
one or more sensory stimulations includes the application of
any noxious, or pain inducing or non-painful means of sen
sory stimulation causing one or more brain responses.
56. The method of claim 53 in which the step of performing
one or more baseline neuroimaging tests includes performing
an electroencephalogram (EEG) test.
57. The method of claim 55 in which the step of applying
one or more sensory stimulations includes selecting for appli
cation one or more sensory stimulations from the group of
sensory stimulations consisting of a tender point test, appli
cation of mechanical pressure on any part of the body, appli
cation of otherforms of mechanical stimulation to any part of
the body, application of an electrical stimulus, application of
a heat-producing stimulus, in vivo or in vitro introduction of
a chemical agent, mechanical brushing, controlled physical
movements made by the Subject, or forms of mental process
ing Such as cognitive exercises.
58. The method of claim 53 in which the step of applying
one or more sensory stimulations includes applying a series
of sensory stimulations that are made over a period of time in
Such a way as to produce multiple brain responses.
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59. The method of claim 53 in which the step of using a
BRT includes assessing changes in brain response over a
period of time.
60. The method of claim 53 in which the step of obtaining
a quantitative assessment of the Subject's brain function
includes assessing changes in brain function in response to a
sensory stimulation.
61. The method of claim 56 in which performance of an
EEG test includes the steps of:
obtaining EEG data for a period of time before the appli
cation of a sensory stimulation;
obtaining EEG data and after the application of any one or
more sensory stimulations; and
performing a mathematical analysis of obtained EEG data.
62. The method of claim 61 in which each step of obtaining
EEG data occurs over a period of time between approxi
mately one second to 15 minutes.
63. The method of claim 53 in which the step of using a
BRT test includes the step of quantifying and recording
parameters associated with the one or more sensory stimula
tions.

64. The method of claim 63 in which the step of quantifying
and recording parameters occurs at or near the time the Sub
ject reports a painful sensation.
65. The method of claim 63 in which the step of quantifying
and recording parameters includes quantifying and recording
parameters that are selected from a group consisting of loca
tion of mechanical pressure, amount of mechanical pressure,
parameters of other forms of mechanical stimuli, parameters
of forms of electrical stimuli, parameters of forms of heat
stimuli, parameters of an introduced chemical agent, param
eters of brush strokes, or parameters of a mental exercise.
66. The method of claim 61 in which the performance of an
EEG test includes the step of recording EEG for a period of
time after application of a final sensory stimulation.
67. The method of claim 66 in which the step of recording
EEG for a period of time after application of a final sensory
stimulation occurs over a period of time between approxi
mately one second and 15 minutes.
68. The method of claim 66 in which the performance of an
EEG test includes the step of producing a resulting EEG data
record that includes the brain response test EEG records
following each one or more applications of one or more
sensory stimulations.
69. The method of claim 68 in which the step of producing
a resulting EEG data record includes the step of providing
clean EEG data sufficient to perform an EEG analysis, and
doing so by extracting non-EEG signals and EEG data
acquired during the application of any one or more sensory
stimulations from each EEG record.

70. The method of claim 61, in which the step of perform
ing a mathematical analysis is performed on a resulting EEG
data record.

71. The method of claim 61, in which the step of perform
ing a mathematical analysis includes the step of selecting one
or more analyses from a group consisting of time domain and
frequency domain parameters.
72. The method of claim 61, in which the step of perform
ing a mathematical analysis includes the step of selecting one
or more analyses from a group consisting of Voltage analysis,
current analysis, Voltage and current analysis, frequency
spectrum analysis using Fast Fourier Transform (FFT) analy
sis, frequency spectrum analysis using a wavelet analysis
method, frequency spectrum analysis using absolute power
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analysis method, frequency spectrum analysis using relative
power analysis method, frequency spectrum analysis using
phase analysis method, frequency spectrum analysis using
coherence analysis method, frequency spectrum analysis
using amplitude symmetry analysis method, phase analysis,
various forms of network analysis and source localization of
electrical activity in the brain using inverse EEG computation
analysis.
73. The method of claim 53 in which the step of making a
statistical comparison includes the step of performing a math
ematical analysis to determine one or more brain measures to
Support a diagnosis of the presence of one or more brain
activities associated with central pain.
74. The method of claim 73, in which the step of perform
ing a mathematical analysis to determine one or more brain
measures to Support a diagnosis of the presence of one or
more brain activities associated with central pain includes the
step of analyzing findings from one or more BRT tests.
75. The method of claim 74, in which the step of analyzing
findings from one or more BRT tests includes performing one
or more analyses to discover one or more brain activities
associated with central sensitivity or abnormal brain network
connectivity associated with pain processing.
76. The method of claim 74, in which the step of analyzing
findings from one or more BRT tests includes the step of
statistically comparing findings of a BRT test to BRT test
records taken from either healthy normal individuals, indi
viduals Suffering from central pain, or individuals that are
suffering from pain that is not central pain.
77. The method of claim 74 in which the step of performing
a mathematical analysis includes making a determination of
EEG abnormalities selected from the group of abnormalities
consisting of abnormal levels of EEG power, abnormal levels
of coherence between at least two EEG sites, abnormal levels

of phase shift between at least two EEG sites, or abnormal
levels of EEG relative power in particular regions of the brain.
78. The method of claim 53, in which the method for

diagnosing and assessing central pain further includes aug
menting assessment of a brain following a BRT by making a
physical assessment.
79. The method of claim 74 including the step of diagnos
ing central pain by:
statistically determining one or more deviations between a
subjects one or more BRT measures and like BRT mea
sures obtained from at least one healthy normal indi
vidual or at least one individual suffering from pain that
is not central pain; then
comparing the one or more deviations to like deviations
detected in a sample population of Subjects known to be
Suffering from central pain.
80-88. (canceled)
89. The method of claim 53, in which the step of diagnos
ing and assessing central pain further includes the step of
determining that at least one abnormal measure of the Sub
ject's brain associated with central pain corresponds to at
least one statistically significant difference finding of a BRT
teSt.

90-97. (canceled)
98. The method of claim 53 in which the step of assessing
a subject’s brain function further includes the step of making
brain measures to identify the presence of one or more brain
activities associated with central pain that is a result of central
sensitivity.
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99. The method of claim 53 in which the step of assessing
a Subject's brain function further includes the step of making
brain measures to identify the presence of one or more brain
activities associated with central pain that is a result of abnor
mal network connectivity.
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